Literature DB >> 19776735

The influence of chronic renal failure on drug metabolism and transport.

A W Dreisbach1.   

Abstract

Chronic renal failure (CRF) has been shown, in animal models and clinical studies, to significantly reduce nonrenal clearance and to alter the bioavailability of predominantly metabolized drugs. Phase II reactions and drug transporters such as P-glycoprotein (P-gp) and organic anion transporting polypeptide (OATP) are also affected. High levels of parathyroid hormone (PTH), cytokines, and uremic toxins are implicated in some of these effects, which have a clinically significant impact on drug disposition and increase the risk of adverse drug reaction.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19776735     DOI: 10.1038/clpt.2009.163

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  24 in total

1.  Urinary CYP eicosanoid excretion correlates with glomerular filtration in African-Americans with chronic kidney disease.

Authors:  Albert W Dreisbach; Stanley V Smith; Patrick B Kyle; Manjunath Ramaiah; Margaret Amenuke; Michael R Garrett; Seth T Lirette; Michael E Griswold; Richard J Roman
Journal:  Prostaglandins Other Lipid Mediat       Date:  2014-08-22       Impact factor: 3.072

2.  Influence of chronic kidney disease and haemodialysis treatment on pharmacokinetics of nebivolol enantiomers.

Authors:  Daniel V Neves; Vera L Lanchote; Miguel Moysés Neto; José A Cardeal da Costa; Carolina P Vieira; Eduardo B Coelho
Journal:  Br J Clin Pharmacol       Date:  2016-04-07       Impact factor: 4.335

3.  Assessment of the effects of renal impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521).

Authors:  Reiner Frey; Corina Becker; Sigrun Unger; Anja Schmidt; Georg Wensing; Wolfgang Mück
Journal:  Pulm Circ       Date:  2016-03       Impact factor: 3.017

4.  Application of a physiologically based pharmacokinetic model informed by a top-down approach for the prediction of pharmacokinetics in chronic kidney disease patients.

Authors:  Hiroyuki Sayama; Hiroaki Takubo; Hiroshi Komura; Motohiro Kogayu; Masahiro Iwaki
Journal:  AAPS J       Date:  2014-06-11       Impact factor: 4.009

Review 5.  Consequences of renal failure on non-renal clearance of drugs.

Authors:  Laure Lalande; Bruno Charpiat; Gilles Leboucher; Michel Tod
Journal:  Clin Pharmacokinet       Date:  2014-06       Impact factor: 6.447

Review 6.  A Synopsis of Clinical Pharmacokinetic Alterations in Advanced CKD.

Authors:  Thomas D Nolin
Journal:  Semin Dial       Date:  2015-04-08       Impact factor: 3.455

7.  Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease.

Authors:  Heyang Wang; Jing Qi; Yi Li; Yunbiao Tang; Chao Li; Jing Li; Yaling Han
Journal:  Br J Clin Pharmacol       Date:  2017-11-03       Impact factor: 4.335

8.  Disease-Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter Consortium.

Authors:  Raymond Evers; Micheline Piquette-Miller; Joseph W Polli; Frans G M Russel; Jason A Sprowl; Kimio Tohyama; Joseph A Ware; Saskia N de Wildt; Wen Xie; Kim L R Brouwer
Journal:  Clin Pharmacol Ther       Date:  2018-07-12       Impact factor: 6.875

9.  Pharmacokinetic and pharmacodynamic profile of rosuvastatin in patients with end-stage renal disease on chronic haemodialysis.

Authors:  Bruce K Birmingham; Suzanne K Swan; Tom Puchalski; Pat Mitchell; Connie Azumaya; Julie Zalikowski; Yi Wang
Journal:  Clin Drug Investig       Date:  2013-04       Impact factor: 2.859

10.  Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron.

Authors:  James Dickinson; Michaelene Lewand; Taiji Sawamoto; Walter Krauwinkel; Marloes Schaddelee; James Keirns; Virginie Kerbusch; Selina Moy; John Meijer; Donna Kowalski; Richard Morton; Kenneth Lasseter; Dennis Riff; Viera Kupčová; Marcel van Gelderen
Journal:  Clin Drug Investig       Date:  2013-01       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.